LONDON, 15th December 2021: Arix Bioscience plc (“Arix”, LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today notes that its portfolio company Depixus has successfully completed its oversubscribed Series A financing which raised €30.6 million (£26.1 million[1]).

Depixus is a biotechnology company developing a unique technology for the fast, accurate, and straightforward extraction of multiomic information from DNA, RNA, and proteins. Funds from the financing will enable Depixus to further develop its proprietary MAGNA™ instrument system, workflows, and reagents towards commercial launch.

Having participated in the first tranche of the Series A financing in February 2021, investing €2.7 million (£2.4 million[2]), Arix now has a 14.2% fully diluted ownership stake in Depixus.

[1] At exchange rate on 14th December 2021

[2] At exchange rate on 25th February 2021

“This is an exciting time for Depixus as it moves forward with its goal to commercialise a highly innovative technology platform for the fast, accurate, and inexpensive extraction of genetic and epigenetic information from single molecules of DNA and RNA. Arix is committed to building breakthrough biotech companies, and it is a privilege to work alongside such a distinguished team of entrepreneurs and co-investors.”

Mark Chin, Managing Director at Arix and Depixus Board Director

The announcement can be accessed on Depixus’ website at: